Health care stocks were edging higher premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was up 0.9% and the iShares Biotechnology ETF (IBB) rose by 1.1% recently.
BeiGene (ONC) shares were slightly down after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of its drug Tevimbra in combination with gemcitabine and cisplatin as a first-line treatment for adults with recurrent or metastatic nasopharyngeal cancer.